Picture of Core Laboratories logo

CLB Core Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsAdventurousMid CapNeutral

Core Laboratories Inc reports results for the quarter ended in December - Earnings Summary

* Core Laboratories Inc  CLB.N  reported quarterly adjusted
earnings of 19 cents​​ per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of 20 cents.  The mean expectation of
eight analysts for the quarter was for earnings of 19 cents per
share. Wall Street expected results to range from 18 cents to 21
cents per share.
    * Revenue rose 0.5% to $128.21 million from a year ago;
analysts
expected $127.77 million. 
    * Core Laboratories Inc's reported EPS for the quarter was
14
cents​.
    * Core Laboratories Inc shares had fallen by 7.4% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 18.2%
in the last three months.​ 
    * In the last 30 days, four analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 6
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the business
support
services peer group is also "hold"

Wall Street's median 12-month price target for Core Laboratories
Inc is $19.50 
This summary was machine generated from LSEG data January 31 at
11:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      0.19           0.19           Met
 Sep. 30 2023      0.22           0.22           Met
 Jun. 30 2023      0.20           0.21           Beat
 Mar. 31 2023      0.16           0.19           Beat

Recent news on Core Laboratories

See all news